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Abstract
Background: Diabetes mellitus is one of the most prevalent diseases worldwide. Diabetes is a chronic
disease associated with micro- and macro-vascular complications and deterioration in general health
status. Therefore, the aim of this study was to estimate general health status among Iranian diabetic
patients through a systematic review and meta-analysis of study utilizing the Short-Form-36 questionnaire.
Methods: Searching the EMBASE, PubMed, ISI/Web of Sciences (WOS), MEDLINE via Ovid, PsycoINFO, as well
as Iranian databases (MagIran, Iranmedex, and SID) from January 2000 to December 2017. The methodological
quality of the studies was evaluated using the “A Cochrane Risk of Bias Assessment Tool: for Non-Randomized
Studies of Interventions” (ACROBAT-NRSI). Random-effect model was used and the means were reported with
their 95% confidence interval (CI). To evaluate the heterogeneity between studies, I2 test was used. Egger’s
regression test was used to assess the publication bias.
Results: Fourteen studies were retained in the final analysis. The mean general health status using SF-36
in diabetic patients of Iran was 51.9 (95% CI: 48.64 to 53.54). The mean physical component summary was
52.92 [95% CI: 49.46–56.38], while the mean mental component summary was 51.02 [95% CI: 46.87–55.16].
Conclusion: The findings of this study showed that general health status in Iranian diabetic patients is
low. Health policymakers should work to improve the health status in these patients and take appropriate
interventions.
Keywords: General health status, Diabetes, Short-Form-36 questionnaire, Iran, Meta-analysis
Background
Diabetes mellitus is one of the most prevalent
diseases worldwide, imposing a relevant epidemio-
logical and clinical burden, both in terms of deaths
and morbidities. The prevalence of diabetes is
increasing both in developed and developing
countries, and has doubled over the past three de-
cades, with almost 80% of diabetic patients living in
less developed countries [1, 2]. Population aging,
lifestyle changes, lack of mobility, and many other
factors characterizing modern life have contributed
to such an increase [3]. In 2014, the prevalence of
diabetes in people aged greater than 18 years in the
world was about 8.5%. It is anticipated that diabetes
will be the seventh cause of death by 2030, and,
despite all efforts to control the disease, it still* Correspondence: masoudbehzadifar@gmail.com
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remains one of the major public health challenges
[4]. The number of people with diabetes is expected
to rise up to about 592 million by 2035 [5]. The
prevalence of diabetes in the Middle East and
North Africa is about 10.9%. In these areas, about
35 million people are affected by diabetes, with Iran
having the highest prevalence (9.94%) among the
countries of the Middle East [6].
Such concerns necessitate adequate health policies
in order to control and prevent diabetes [7]. This
disorder represents a chronic disease associated
with micro- and macro-vascular complications,
which dramatically impact on general health status
[8]. Studies have shown that such complications can
affect physical, mental and social life of people,
modifying and interfering with their usual every day
functioning [9]. Hence, treatments of diabetes are
usually evaluated based on their effect on health
status [10], which, as a key factor in effectiveness
studies, refers, indeed, to the mental, physical and
social status of the patient [11]. Considering the
general health status among diabetic patients can
provide care givers with a better understanding of
patients’ conditions, indicating which health
provisions are necessary for a proper management
of the disease [12].
To assess general health status among diabetes
patients, a variety of questionnaires have been
developed that can measure different dimensions of
the patients’ life. The Short-Form 36 (SF-36)
questionnaire is one of the most commonly used
instruments [13]. It includes 36 questions
distributed across eight domains (namely, vitality,
physical function, body pain, health perception,
physical role, emotional role, social role and men-
tal health) [14, 15].
Various studies have been conducted to assess
Iranian diabetic population’s quality of life. Such in-
formation can be helpful for measuring the severity
of complications and designing and implementing
appropriate healthcare policies. In 2013, a review
study was conducted in Iran on health status in
diabetic patients. In this study, the assessment of
health status of diabetics was based on all question-
naires used in Iran. Authors suggested that a
meta-analysis study could better provide informa-
tion about health status in diabetic patients [16].
Therefore, the aim of this study was to estimate
Fig. 1 Flowchart of the study retrieval and selection
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general health status among Iranian diabetic pa-
tients through a systematic review and
meta-analysis of studies utilizing a specific instru-
ment, namely the SF-36 questionnaire.
Methods
Literature search
The current study has been performed according to the
“The Meta-analysis of Observational Studies in Epidemi-
ology” (MOOSE) guidelines [17]. (Additional file 1).
Two authors independently searched different schol-
arly electronic databases: namely, EMBASE, PubMed,
ISI/Web of Sciences (WOS), MEDLINE via Ovid, Psy-
coINFO, as well as Iranian databases (MagIran, Iranme-
dex, and SID). These databases were systematically
searched from January 2000 to December 2017 using the
following search strategies: (“general health status”)
AND (“Short form 36” OR “SF-36” OR “SF-36 health
survey questionnaire” OR “Short form-36 health survey
questionnaire”) AND (“Diabetes” OR “Diabetic”) AND
“Iran”. Studies were searched both in English and Per-
sian (no language filter applied). Reference lists of each
included study were also scanned and hand-searched for
possible related studies.
Inclusion/ criteria
Studies with the following criteria were included if: i)
utilizing the SF-36 questionnaire for investigating gen-
eral health status among Iranian populations, ii) report-
ing an average score for the eight domains of the
questionnaire, iii) reporting both Physical Component
Summary (PCS) and Mental Components Summary
Fig. 2 The result of quality assessment of risk of bias of included studies
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(MCS) indicators, and iv) reporting means with standard
errors (SE) or standard deviations (SD). Both
cross-sectional or case-control studies were considered.
Exclusion criteria
Studies were excluded if: i) designed as reviews, let-
ters to the editor, editorials, expert opinions, com-
mentaries, clinical trials, case-reports, case-series, or
ii) not reporting quantitative details of the SF-36
questionnaire.
Quality assessment
The methodological quality of the studies was evalu-
ated using the “A Cochrane Risk of Bias Assessment
Tool: for Non-Randomized Studies of Interventions”
(ACROBAT-NRSI) [18].
Data extraction
Two authors (MB and NLB) extracted the data from the
studies, and if there was a controversy between them,
another author (AA) resolved the issue. The name of
first authors of the studies, the year of publication, the
place where the studies were conducted, the number of
participants, the duration of diabetes, the design, and
the mean scores of SF-36 domains were extracted.
Statistical analysis
The pooled value of the mean of overall scores, as well
the scores of the eight domains of the questionnaire and
the PCS and MCS scores were calculated as the mean
and SE. Random-effect model was used and the means
were reported with their 95% confidence interval (CI).
Fig. 3 The Mean health status in Iranian diabetic patients (2011–2017), based on the random-effects model
Fig. 4 Probability of publication bias in the included studies
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To evaluate the heterogeneity among studies, I2 test was
used [19]. For evaluating the potential sources of hetero-
geneity, subgroup analyses based on the study design,
sample size and type of diabetes (type 1 and type 2 dia-
betes) were conducted. Sensitivity analysis was per-
formed to ensure that the results were stable. This
analysis was also performed based on the year of publi-
cation. Egger’s regression test was used to assess the
publication bias [20].
Finally, case-control studies were pooled together,
computing the standardized mean difference (SMD).
Figures with a p-value < 0.05 were considered statisti-
cally significant. All data were analyzed using Stata 12.0
software (Stata Corp LP, College Station, TX).
Results
After the initial electronic database search, 378 studies
were found. Eighty-three duplicate studies were deleted.
The titles of the retrieved studies were reviewed and 258
studies were excluded due to lack of relevance to the
topic. Then, the title and abstract of 37 remaining stud-
ies were reviewed by two authors independently and 21
studies were excluded with reason. Finally, the full texts
of the remaining 16 studies were examined and, based
on the inclusion/exclusion criteria, 14 studies were
retained in the final analysis [21–34]. Figure 1 summa-
rizes the stages of the retrieval and selection of the
studies.
The included studies were conducted between 2011
and 2017. The total number of participants in the stud-
ies was 4492, ranging from 60 to 1847 people. The study
designs varied across studies and were cross-sectional
for 10 studies and case-control for 4 studies). Table 1
shows the main characteristics of the studies retained in
the present systematic review and meta-analysis.
The quality assessment of the risk of bias of the in-
cluded studies is shown in Table 2 and Fig. 2.
The mean general health status using SF-36 based on
the random-effect model in diabetic patients of Iran was
51.9 (95% CI: 48.64 to 53.54). The lowest health status
was observed in the study of Saadatjoo with a score of
28.52 and the highest in Kashifi’s study, with a value of
61.33. Figure 3 shows the overall general health status
among the included studies.
Using the Egger’s test, no publication bias could be de-
tected (p = 0.859, see Fig. 4).
To investigate the possible sources of heterogeneity
between studies, subgroup analysis was conducted based
on study design, sample size and study quality. Table 3
shows the results of subgroup analysis.
For further evaluation of sources of heterogeneity, the
results of meta-regression were analyzed based on the
year of publication and the sample size of studies, as
presented in Table 4. The results showed that the quality
of life of diabetic patients has increased on a yearly basis
Table 3 The results of subgroup analysis
Variables Number of
studies
Number of
participants
Mean score of general health
status (95% CI)
I2 P-value
Design of studies
Cross-sectional 10 4077 52.32 (50.02–54.62) 86.8% 0.001
Case-control 4 415 46.47 (38.87–54.08) 93.3% 0.001
Sample size
≤120 6 614 49.58 (43.11–56.05) 92% 0.001
> 120 8 3878 51.60 (48.95–54.24) 90.7% 0.001
Type of diabetes
Type 2 11 3702 50.46 (47.43–53.49) 92.46% 0.001
Both type (type 1 and 2) 3 790 53.22 (51.37–55.07) 0% 0.001
Table 4 The results of meta-regression
Variables Coefficient S.E. t P-value Lower 95% Upper 95%
Year 1.36 1.07 1.27 0.22 −0.99 3.73
Sample size −0.00 0.00 −0.22 0.82 −0.01 0.00
Table 5 The health status based on the 8 domains of the SF-36
questionnaire
Variables Mean (95% CI) Heterogeneity P-value of
publication bias
I2 P-value
Physical function 61.62 (55.70–67.53) 98.6% 0.001 0.78
Role physical 49.96 (44.50–55.41) 95.6% 0.001 0.83
Body pain 52.26 (48.47–56.04) 95.8% 0.001 0.57
General health 47.34 (44.15–50.53) 96.5% 0.001 0.01
Vitality 46.99 (43.28–50.69) 97.4% 0.001 0.64
Social function 57.86 (46.87–68.85) 99.7% 0.001 0.15
Role emotional 50.38 (45.29–55.47) 97.4% 0.001 0.28
Mental health 47.79 (40.06–55.52) 99.6% 0.001 0.32
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and has decreased based on the sample size. However,
none of the results were statistically significant.
The results based on the eight domains of the SF-36
questionnaire are presented in Table 5. The mean scores
of PCS and MCS are shown in Figs. 5 and 6. The mean
of PCS was 52.92 [95% CI: 49.46–56.38], while the mean
of MCS was 51.02 [95% CI: 46.87–55.16].
Finally, case-control studies were pooled together
(Fig. 7). The general health status of diabetic patients
compared to healthy controls was lower with a SMD of
− 0.84 [95% CI: -1.83 to 0.51] and compared to the
group of patients with tuberculosis with a SMD of 0.44
[95% CI: 0.21- 0.67].
Discussion
In the 14 studies included in this systematic review and
meta-analysis, numerous complications and
co-morbidities were reported in people with diabetes.
Health policy- and decision-makers should pay attention
to the implications of the reduced general health status
in diabetic patients in Iran. Various studies have, indeed,
shown that health status is an independent prognostic
predictor of survival and hospitalization rate in patients
with peripheral arterial and renal patients, and of mor-
tality in patients with coronary heart disease [35–38].
General health status is decreased in diabetic patients
[39], when compared to the health status of general
population, which, in a recent study, reported an average
score of 67.69 ± 14.78 [40]. Healthcare providers should
be aware of the patients’ perspective and their perceived
health. Preventing further diabetes complications and
providing better conditions for patients’ lives is funda-
mental. Physical and mental interventions can improve
the health status of diabetic patients and avoid, or at
least delay, further deterioration [41].
Our findings showed that the dimensions of physical
and social function had the highest score whereas the
lowest score was related to vitality and general health.
The results of our study are consistent with the study
done in Brazil [42], whereas other studies reported
higher values [43–45]. The level of access to health ser-
vices, the economic and social conditions of people, the
physical and mental conditions of individuals can, at
least partially, explain these differences [46, 47]. Some
Fig. 5 The Physical component summaries (PCS)
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studies point to the existence of health inequalities in
that people with a higher socioeconomic status have
more incentive and energy to change their livelihood
and are more involved in their own health care processes
[48]. An important cross-sectional survey of 13 national
samples from Asia, Australia, Europe and North Amer-
ica of 5104 patients with diabetes from the multinational
study of Diabetes Attitudes, Wishes and Needs (DAWN)
has shown that the reported levels of well-being,
self-management, and diabetes control correlate with
Fig. 6 The mental component summaries (MCS)
Fig. 7 The results of pooling together case-control studies
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country, respondent demographic and disease character-
istics, as well as with healthcare features [49]. These
findings have been replicated by a follow-up study [50].
The findings of the present study indicate that diabetes
dramatically affects vitality and general health domains;
hence these areas should be given more attention when
treating diabetic patients. In our study, MCS was less
than PCS, which was consistent with the results of the
Al-Shehri study [51]. Various studies have been con-
ducted to show that mental disorders such as depression
in patients with diabetes can be remarkably observed. In
a review, results showed that depression in diabetic pa-
tients had a negative effect on the treatment process and
increased complications of the disease [52].
It seems that the chronic and severe nature of diabetes
mellitus in the long run leads to a decrease in the gen-
eral health status [53]. It should be noted that the core
of the concept of reported/perceived health status is a
feeling/perception of one’s own health and, in fact, other
aspects of the health status form a sense of health that is
low in patients with diabetes. Affecting the emotional as-
pects impacts on energy and vitality of patients with dia-
betes. Other studies have also shown a decrease in
vitality, with an increase of fatigue, depression, anxiety
and stress problems, among patients with diabetes.
Therefore, diabetes has a long-term negative effect on
the health of patients. The decrease in the health status
in patients with diabetes has also been replicated in
other studies [54].
These observations can be confirmed if we compare
health status of Iranian subjects with diabetes with the
health status of people with chronic-degenerative disor-
ders, such as rheumatoid arthritis with an average score
of 52.47 [55], or cardiovascular disorders with a mean of
53.19 [56], among others. Similarly, low scores have been
found for asthma [57] or chronic kidney disease [58].
Scores even lower (40.43 ± 12.7) were reported for indi-
viduals with drug addiction [59].
In meta-analysis studies, taking into account potential
sources of heterogeneity is crucial [60]. To investigate
this aspect, we performed subgroup-analysis based on
each SF-36 scale domain. The results of meta-regression
were also studied for further evaluation of heterogeneity
sources, which showed an increased average health sta-
tus of diabetic patients based on the year of publication,
even though not statistically significant. In recent years
the status of services provided to diabetics is on the rise,
but it seems that many of the services provided to them
are not of sufficient standards, and the quality of care
for these patients should be monitored more closely by
healthcare providers in Iran.
However, this study has some limitations that should
be properly mentioned. First, the primary studies missed
to give some complementary information about patients,
such as sex, other illnesses/co-morbidities, education
level and income. Second, a high level of heterogeneity
was observed, which can be attributed to methodological
differences. Third, the health status in diabetic patients
has not been studied in many Iranian provinces, which
can challenge the generalizability of our estimation to all
Iranian diabetic population.
Conclusion
The findings of this study showed that general health
status in Iranian diabetic patients is low. Health policy-
and decision-makers should work to improve the health
status in these patients and take appropriate interven-
tions. Therefore, it is recommended to look at important
factors such as patients’ attitudes in changing and im-
proving their lifestyle. A combination of both clinical
and non-clinical interventions should be targeted at in-
creasing the standard of living of these patients.
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